Paul Feuerstadt, MD: Exciting New Data on RBX2660

Video

If approved by the FDA, RBX2660 would be the first approved live microbiota therapeutic for the treatment of recurrent CDI.

This may be the homestretch for a promising new treatment for recurrent Clostridium difficile infections (rCDI).

At the 2022 American College of Gastroenterology (ACG) Annual Meeting, there are at least 7 abstract presentations on the safety and efficacy of RBX2660, a live microbiota therapeutic for the treatment of rCDI.

The presentations come just a few weeks after the US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to recommend a Biologics License Application (BLA) for the treatment. If approved, RBX2660 would be the first live microbiota therapeutic to gain FDA approval.

Paul Feuerstadt, MD, Assistant Clinical Professor of Medicine, Yale School of Medicine, an author on all 7 studies,told HCPLive®, the data is positive, even when broken down between different age and other subgroups from the PUNCH CD3 study.

In 1 of the studies, the investigators found similar proportions of patients treated with RBX2660 categorized by age and Charlson Comorbidity Index (CCI) severity scores experienced treatment emergent adverse events.

The treatment, developed by Ferring Pharmaceuticals, is aimed at reducing recurrent CDI after antibiotic usage by being administered as a pre-packaged single-dose, consisting of 150 mL microbiota suspension from individual human stool donation.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.